DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
LY2623091 is an investigational drug.
There have been 5 clinical trials for LY2623091. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2014.
The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Kidney Diseases, and Hypertension. The leading clinical trial sponsors are Eli Lilly and Company and [disabled in preview].
There is one US patent protecting this investigational drug and forty-one international patents.
Recent Clinical Trials for LY2623091
|A Study of LY2623091 in Healthy Participants||Eli Lilly and Company||Phase 1|
|A Study of How the Body Breaks Down and Eliminates LY2623091||Eli Lilly and Company||Phase 1|
|A Study of LY2623091 in Participants With High Blood Pressure||Eli Lilly and Company||Phase 2|
Top disease conditions for LY2623091
Top clinical trial sponsors for LY2623091
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|LY2623091||Start Trial||Mineralocorticoid receptor antagonists and methods of use||Eli Lilly and Company (Indianapolis, IN)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|